FDA Criticizes Xgeva Drug for Prostate Cancer
A latest report has unveiled that the Food and Drug Administration has voted against the wider use of Amgen Inc's drug Xgeva that is used for prevention of prostate cancer. It is being claimed by the FDA board that the benefits of Xgeva are not able to offset the risk of prostate cancer which could affect bones.
Time Not Going Well for Walgreen Co.'s, January Sales Found Short of Expectations
As per latest information, it has been revealed that the decision made recently by Walgreen Co., as per which it decided to steer clear of the pharmacy network of a flourishing and one of its largest customers, along with a gentle cold-and-flu period, has perhaps resulted in dragging down its sales for the month of January by around 2.3%, which now reads $5.8 billion.
Pfizer Calls Back Pregnancy Drugs
Pfizer, one of the largest drug firms in the world, has admitted to have made a major blunder lately. For the same reason, they have had to call back about a million birth control tablets. This is because there has been an error due to which the drugs have got mixed in their packaging.
FDA Nods in Favor of Cystic Fibrosis Drug
In a recent study, the Food and Drug Administration has given green signal to a drug which can cure cystic fibrosis. However, the drug, Kalydeco, from Vertex Pharmaceuticals Inc., would not be that easy to get as it may cost one to shell out as much as $294,000 a year.
FDA Approves New Twice a Week Diabetes Drug
It has been recently revealed in a report that the new drug developed by Amylin Pharmaceutical Company from San Diego has been given approval by the Food and Drug Administration in the U. S.
It has been further revealed that with the mere decision of the approval being out, the shares of the firm have seen a rise of 17% recently.
Pfizer's Inlyta Approved by US FDA for Kidney Cancer
Marking a grand success for the drugmaker Pfizer, its medicine Inlyta for patients suffering from advanced stages of kidney cancer has reportedly bagged a green light from the drug regulators in the United States, thereby marking a significant escalation in the efforts being made by the drug manufacturer with the intent of offsetting the sales of Lipitor.
Fabrazyme Gets Approval From FDA
It was recently revealed by the firm Genzyme Corp, which is the Cambridge segment of the French firm Sanofi, that their drug Fabrazyme has been approved by the FDA for starting production again. The firm recently said that this new drug, which is meant for the cure of Fabry disease, has been approved for production by the Food and Drug Administration in the United States.
EMA Investigates Efficacy Of Novartis Pill Gilenya
After coming across few death cases due to Novartis AG's multiple-sclerosis drug Gilenya, the European Medical Agency (EMA) has started an investigation which would see its pros and cons. The EMA said that the main reason to conduct the review is to make sure that the drug is safe.
FDA Rejects New Diabetes Drug for Now
It has been recently revealed that the drug for diabetes which was under trial by the FDA is not passed for authenticity for now. They are of the view that there is need for more research and data on the drug, before they can approve it. The name of the drug is dapagliflozin and the FDA is of the view that there is need to prove its worth according to safety, before it can be approved.
Roche Melanoma Pill Can Cause Mild Skin Cancer, Study Reveals
A recent research, which was carried out by a team of researchers from the University of California, Roche and Daiichi Sankyo's Plexxikon, has revealed that Roche Holding's pill Zelboraf taken frequently by melanoma patients can result in imparting high risk of developing a rare and less harmful type of skin cancer, dubbed cutaneous squamous cell carcinoma.
No Alzheimer’s Cure in Dimebon
It has been recently revealed that the drug firms, Mediation and Pfizer, have called it quits in the clinical testing for the drug dimebon. This was the crucial testing stage for the drug, and the firms deeming it useless, have done away with it.
Roche’s Drug for Ovarian Cancer Cure Available in the UK
Recent reports have found that a first-line treatment for ovarian cancer, known as Roche's Avastin, is now available in the United Kingdom. The drug would act as a standard treatment in combination with the chemotherapy and surgery.
Cochrane Collaboration Doubts the Efficacy of Tamiflu
The-Cochrane-Collaboration.gif
As per reported information, the Cochrane Collaboration has blamed pharmaceutical giant Roche for withholding information in regard to its swine flu pandemic drug Tamiflu. Earlier, in 2009 a review got published in the British Medical Journal about Tamiflu.
CVS Caremark to pay $5 million As Damages to Customers
Finally, CVS Caremark, a company which manages the prescription drug plans for employers and insurers have agreed to pay $5 million to their customers in the form of damages, said the Federal Trade Commission.
Novartis Recall Products Due to Safety Concerns
The Food and Drug Administration has recently issued a warning over contamination of some of the drugs from Novartis. Following the warning, Novartis has issued a recall of 1,645units of its Excedrin, NoDoz, Bufferin and Gas-X medicines.
Aveo Seeks Approval for New Kidney Cancer Drugs
Aveo Pharmaceuticals said it was not able to match the level of expectations which the drug investors had from their experimental medicine for kidney cancer. The experimental medicine called tivozanib was able to provide better survival rate to patients with advanced renal cell carcinoma for about a year.
New Drug for Fighting Pneumonia in Adults
It has been recently revealed that the Food and Drug Administration has recently approved the use of Prevnar, 13, from Pfizer. This drug is meant for treating pneumococcal conjugat, for the prevention of pneumonia.
Pfizer Accused Of Lowering Lipitor’s Price To Gain Domination In the Generic Market
It has been reported that Pfizer has been accused of using unauthentic practices of lowering the prices of its drug to gain domination in the generic market. For long enjoying the monopoly for its drug Lipitor, the drug manufacturer Pfizer has entered into the generic market, as the patent of its Lipitor expired last month.
Drug Firms Seeing Downfall, Due to Failed Tests
It has been recently revealed by the drug firms Novartis AG and AstraZeneca Plc that their drugs undergoing trial for late-stage development for curing hypertension and depression have failed to prove their authenticity in the studies. This has also given rise to rumors about what sort of effect this shall tend to have on their sales and profits in the time to come.
Lipitor Faces Tough Competition From Generic Versions
In a recent report, it has been made clear that the sales of cholesterol blockbuster Lipitor have tumbled down by 50% in a single week as the market is flooded with new prescriptions for generic Lipitor. Though stern efforts were made by Lipitor maker Pfizer to ensure that patients stray with their pull, it was observed that majority of the patients had switched their preference.